FDA Says No To TSRO, Ablynx On Track, MYL Leads In Herceptin Biosim Race In U.S.

The FDA has refused to approve TESARO Inc.'s (TSRO) intravenous formulation of Rolapitant, developed for the prevention of chemotherapy-induced nausea and vomiting.

from RTT - Biotech http://ift.tt/2jGFEyd
via IFTTT